ORLANDO, Fla. – PerkinElmer Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today announced the introduction of LABWORKS LIMS v5.9 – the first release built on an entirely new computing platform – at PITTCON® 2006, Booth 2669.

The new architecture of v5.9 provides users with a new toolkit to easily and infinitely customize site-specific data structure and presentation utilized by the LIMS modules.  By virtually eliminating the need for users to write their own custom interfaces, LABWORKS LIMS v5.9 significantly reduces implementation time and costs, as well as long-term cost of ownership. 

“We’ve used the state-of-the-art Microsoft*.Net development platform to create an architecture that provides users with an unprecedented ability to custom-tailor their own systems,” commented Jonathan Rennert, vice president and general manager, Analytical Sciences, for PerkinElmer’s Life and Analytical Sciences division.  “The bottom line is that we put the customers in the driver’s seat.  They can easily add functionality as their needs change and evolve.”  

A new Data Class Designer Tool enables users to easily add and integrate customized data fields and build their own structures for information availability.  The new Template Designer layout tool allows the user to control how information is presented and organized, with a redesigned, integrated query mechanism that eliminates imposed hierarchies to significantly streamline data searches.  “You no longer need to think like a LIMS developer to query your data,” added Rennert.

The LABWORKS Desktop has been redesigned to support customer-defined workflow navigation.  Module folders, along with the related files, reports and templates, are displayed in a familiar Windows* format for greater ease-of-use.  Users can also create multiple levels of folder sharing or designate restrictions to specific folders.  Other key functionality advances include
 
expanded security features that facilitate regulatory compliance with ISO 17025 and other standards.  An embedded Cyrstal Reports** tool, unique to LABWORKS LIMS, streamlines reporting.

With this new v5.9 release, PerkinElmer is continuing to apply its Project Team approach for LIMS implementations that meet customer site-specific requirements.  The LABWORKS proprietary discovery process identifies unique bottlenecks and challenges in each customer environment.  “Our implementation time is significantly less than what is required for competitive systems,” explained Rennert.  “With two decades of customer service expertise, we are known for our support and ability to get systems up and running quickly and cost-effectively.”
For more information on LABWORKS LIMS v5.9, visit www.labworks.com or call 1-800-762-4060.
*Windows is a registered trademark of Microsoft Corporation.
** Crystal Reports is a registered trademark of Business Objects.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements.  Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct.  A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements.  These factors include, without limitation: (1) economic and geopolitical forces that may limit any continued or expected economic or end market strengthening or recoveries; (2) risks related to our failure to introduce new products in a timely manner; (3) our ability to comply with financial covenants contained in our credit agreements and our debt instruments; (4) a delay in resolution of the Company’s tax audits and an adverse determination with respect to the Company’s tax audits by the Internal Revenue Service or other taxing authorities; (5) cyclical downturns continuing to affect several of the industries into which we sell our products; (6) our ability to adjust our operations to address unexpected changes; (7) our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business; (8) the loss of any of our licenses that may require us to stop selling products or lose competitive advantage; (9) competition; (10) regulatory compliance; (11) regulatory changes; (12) our failure to obtain and enforce intellectual property protection; (13) our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets; (14) other factors which we describe under the caption “Forward-Looking Information and Factors Affecting Future Performance” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings  with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information

Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging.  Photonics markets include sensors and specialty lighting.